A Randomized, Controlled, Blinded, Parallel Group Study of the Safety and Efficacy of APC-0101 (SF-RI 1 Surfactant for Inhalation Combined With a Dedicated Delivery System) in Preterm Infants With Respiratory Distress Syndrome
A Randomized, Controlled, Blinded, Parallel Group Study of the Safety and Efficacy of APC-0101 (SF-RI 1 Surfactant for Inhalation Combined With a Dedicated Delivery System) in Preterm Infants With Respiratory Distress Syndrome
This is a 2-part, prospective, randomized, blinded, sham-controlled, multi-center study comparing preterm subjects with RDS who are treated with APC-0101 and nCPAP/NIV to subjects treated with nCPAP/NIV alone (Sham). In Part 1, subjects will be followed until they reach 40 weeks post-menstrual age (PMA) or are discharged from the NICU, whichever comes first. In Part 2, subjects will undergo post-term follow-up through 24 months corrected age.
Inclusion Criteria:
Exclusion Criteria:
AF3inquiries@aerogenpharma.com9196026411
Little Rock, Arkansas 72205, United States
vchawla@uams.edu631-682-0812
New York, New York 10032, United States
NICUstudies@health.ucsd.edu858-249-1711
megan.mathews@ufhealth.org904-244-5450
Narendra.Dereddy.MD@adventhealth.com407-609-3280
awallace@beaconhealthsystem.org574-647-3048
John.Ladino@atlantichealth.org973-971-5488
r262@cumc.columbia.edu212-305-8500
Ibadete.xama@einsteinmed.edu
edmund_lagamma@nymc.edu914-493-8558
Terriel.newsom@christushealth.org210-704-2823
hvw8cy@uvahealth.org
mpolak@hsc.wvu.edu304-293-1202